Skip to main content
. 2014 Jan 7;20(1):183–192. doi: 10.3748/wjg.v20.i1.183

Table 2.

Association between anaplastic lymphoma kinase copy number gain and clinicopathological characteristics of hepatocellular carcinoma patients n (%)

Characteristics Total cases ALK/CNG
P value
Positive (28 cases) Negative (185 cases)
Age (yr)
< 49 105 12 (11.4) 93 (88.6) 0.465
≥ 49 108 16 (14.8) 92 (85.2)
Sex
Female 17 3 (17.6) 14 (82.4) 0.843
Male 196 25 (12.8) 171 (87.2)
Grade
I + II 116 12 (10.3) 104 (89.7) 0.186
III + IV 97 16 (16.5) 81 (83.5)
Stage
I + II 174 21 (12.1) 153 (87.9) 0.326
III + IV 39 7 (17.9) 32 (82.1)
Relapse
No 83 13 (15.7) 70 (84.3) 0.385
Yes 130 15 (11.5) 115 (88.5)
AFP (ng/mL)
< 400 125 19 (15.2) 106 (84.8) 0.290
≥ 400 88 9 (10.2) 79 (89.8)
Child-Pugh- classification
A 195 25 (12.8) 170 (87.2) 0.922
B + C 18 3 (16.7) 15 (83.3)
HBV DNA
Positive 113 17 (15.0) 96 (85.0) 0.383
Negative 100 11 (11.0) 89 (89.0)
Postoperative platelet count
< 100 × 109/L 35 2 (5.7) 33 (94.3) 0.250
≥ 100 × 109/L 178 26 (14.6) 152 (85.4)

ALK/CNG: Anaplastic lymphoma kinase copy number gain; AFP: Alpha fetoprotein; HBV: Hepatitis B virus.